This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

ESMO-Asia, Singapore 22-24 November 2019

A Phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: a biomarker analysis​

Rafael Rosell, Artem Poltoratskiy, Maximilian Hochmair, Konstantin K. Laktionov, Rodryg Ramlau, Jana Skrickova, Simona Rizzato, Paolo Bidoli, Dariusz Kowalski, Laura Clementi, Agnieszka Cseh, Filippo de Marinis

esmo_asia_2019_-_1200_55_biomarker_poster.jpg

Related Materials

Learn more about the science behind this poster in the videos, papers and other materials below.

The value of real-world evidence to clinical practice

Real-world evidence complements clinical trials by providing information on the effectiveness and side-effect profile of therapies in patients treated in routine clinical practice.

The value of real-world evidence to clinical practice

Rate this

FOR HEALTHCARE PROFESSIONALS ONLY.

image